Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present disclosure relates to triazolopyrimidine compounds, compositions comprising such compounds, and their use for the treatment of Polycomb Repressive Complex 2 (PRC2)-mediated diseases or disorders.
• PRC2 Polycomb Repressive Complex 2
• Polycomb group (PcG) proteins are chromatin modifying enzymes that are dysregulated in many human cancers.
• the Polycomb Repressive Complex 2 (PRC2) which includes SUZ12 (suppressor of zeste 12), EED (embryonic ectoderm
• EZH2 enhanced of zeste homolog 2
• PRC2 is the critical component of cellular machinery involved in the epigenetic regulation of gene transcription and plays critical function in development and tissue differentiation and regeneration.
• EZH2 is the catalytic subunit, PRC2 requires at least EED and SUZ12 for its methyltransferase activity. EED, SUZ12 and EZH2 are overexpressed in many cancers, including but not limited to breast cancer, prostate cancer, hepatocellular carcinoma and etc.
• EZH2 activating mutations have been identified in DLBCL (diffused large B cell lymphoma) patients and FL (follicular lymphoma) patients.
• DLBCL diffuseused large B cell lymphoma
• FL follicular lymphoma
• PRC2 methyltransferase activity by compounds competing with the cofactor S-adenosyl methionine (SAM) in DLBCL reverses H3K27 methylation, re-activates expression of target genes and inhibits tumor growth/proliferation. Therefore, PRC2 provides a pharmacological target for DLBCL and other cancers.
• SAM cofactor S-adenosyl methionine
• R 1 , R 2 , R 3 , R 4 , R 5 , and n are as defined herein, including stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, or solvates thereof, which are useful for the treatment of PRC2-mediated diseases or disorders.
• the present disclosure also provides processes and intermediates for making the compounds of the present disclosure.
• the present disclosure also provides pharmaceutical compositions comprising at least one of the compounds of the present disclosure and at least one pharmaceutically acceptable carrier, diluent or excipient.
• the pharmaceutical composition may further comprise at least one additional therapeutic agent.
• additional therapeutic agents selected from: other anti-cancer agents, immunomodulators, anti-allergic agents, anti-nausea agents (or anti-emetics), pain relievers, cytoprotective agents, and combinations thereof.
• the compounds of the present disclosure may be used in the treatment of diseases or disorders mediated by EED and/or PRC2.
• the compounds of the present disclosure may be used in therapy.
• the compounds of the present disclosure may be used for the manufacture of a medicament for the treatment of diseases or disorders mediated by EED and/or PRC2.
• the present disclosure provides a method for the treatment of diseases or disorders mediated by EED and/or PRC2, comprising administering to a patient in need thereof a therapeutically effective amount of a first therapeutic agent optionally with a second therapeutic agent, wherein the first therapeutic agent is a compound of the present disclosure and the second therapeutic agent is one other type of therapeutic agent.
• Examples of diseases or disorders mediated by EED and/or PRC2 include, but are not limited to, diffused large B cell lymphoma (DLBCL), follicular lymphoma, other lymphomas, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, brain tumors including neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, and soft tissue sarcomas such as rhabdomyosarcom
• the present disclosure provides a method for the treatment of diseases or disorders mediated by EED and/or PRC2, comprising administering to a patient in need thereof a therapeutically effective amount of a first therapeutic agent optionally with a second therapeutic agent, wherein the first therapeutic agent is an EED inhibitor and the second therapeutic agent is one other type of therapeutic agent; wherein the diseases or disorders are selected from diffused large B cell lymphoma (DLBCL), follicular lymphoma, other lymphomas, leukemia, multiple myeloma, gastric cancer, malignant rhabdoid tumor, and hepatocellular carcinoma.
• DLBCL diffused large B cell lymphoma
• follicular lymphoma other lymphomas
• leukemia multiple myeloma
• gastric cancer malignant rhabdoid tumor
• hepatocellular carcinoma hepatocellular carcinoma
• the compounds of the present disclosure can be used alone, in combination with other compounds of the present disclosure, or in combination with one or more, preferably one to two other agent(s), simultaneously or sequentially.
• the present disclosure provides, inter alia, a compound of
• R 1 and R 2 are independently H or halogen
• R 3 is independently selected from: halogen, phenyl, and a 5- to 6-membered heteroaryl comprising carbon atoms and 1 -4 heteroatoms selected from N, NR a , O, and S(0) p ; wherein said phenyl and heteroaryl are substituted with 0-3 R 3A ;
• each R 3C is independently selected from: C 3 -C 6 cycloalkyl, phenyl, and a 4- to 7- membered heterocycle comprising carbon atoms and 1 -4 heteroatoms selected from N, NR a , O, and S(0) p ; wherein each moiety is substituted with 0-2 R c ;
• each R 3D is independently selected from: C C 4 alkyl and R 3C ;
• R 3E and R 3G are, at each occurrence, independently selected from: H and C C 4 alkyl;
• each R 3F is independently selected from: H and C C 4 alkyl substituted with 0-1
• R 4 is independently selected from: H, halogen and C C 4 alkyl
• R 5 is independently selected from OH and C C 4 alkyl
• R b is independently selected from: halogen, OH and C C 4 alkoxy;
• R d is independently selected from: OH and NR e R f ;
• R e and R f are, at each occurrence, independently selected from: H and
• each p is independently selected from 0, 1 and 2;
• n and n are, at each occurrence, independently selected from 0 and 1 .
• R 1 and R 2 are independently H or halogen
• R 3 is independently selected from: halogen, phenyl, and a 5- to 6-membered heteroaryl comprising carbon atoms and 1 -4 heteroatoms selected from N, NR a , O, and S(0) p ; wherein said phenyl and heteroaryl are substituted with 0-3 R 3A ;
• each R 3C is independently selected from: C 3 -C 6 cycloalkyl, phenyl, and a 4- to 7- membered heterocycle comprising carbon atoms and 1 -4 heteroatoms selected from N, NR a , O, and S(0) p ; wherein each moiety is substituted with 0-2 R c ;
• each R 3D is independently selected from: C C 4 alkyl and R 3C ;
• R 3E and R 3G are, at each occurrence, independently selected from: H and
• each R 3F is independently selected from: H and C C 4 alkyl substituted with 0-1 R d ;
• R 4 is independently selected from: H, halogen and C C 4 alkyl;
• R 5 is independently C C 4 alkyl;
• R b is independently selected from: halogen, OH and C 1 -C 4 alkoxy;
• R d is independently selected from: OH and NR e R f ;
• R e and R f are, at each occurrence, independently selected from: H and d-C 4 alkyl;
• each p is independently selected from 0, 1 and 2;
• n and n are, at each occurrence, independently selected from 0 and 1 .
• the present disclosure includes a compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, within the scope of the first aspect; wherein:
• R 4 is H
• n is independently selected from 0 and 1 ;
• n 0.
• the present disclosure includes a compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, within the scope of the first or second aspect; wherein:
• R 1 is independently H or F
• R 2 is H
• R 3 is independently selected from: phenyl and a 6-membered heteroaryl comprising carbon atoms and 1 -2 heteroatoms selected from N and NR a ; wherein said phenyl and heteroaryl are substituted with 0-3 R 3A .
• the present disclosure includes a compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, within the scope of any one of the first, second and third aspects; wherein:
• R 3 is independently selected from: phenyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl; wherein each moiety is substituted with 0-3 R 3A .
• the present disclosure includes a compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, within the scope of any of the first to fourth aspects, wherein:
• R 3 is independently selected from:
• the present disclosure includes a compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, within the scope of any of the first to fifth aspects, wherein:
• R 3B is independently selected from: OH, NH 2 , NH(C C 4 alkyl), N(d-d alkyl) 2 ,
• the present disclosure includes a compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, within the scope of any of the first to sixth aspects, wherein:
• R 3 is independently selected from: ;
• R is independently selected from: OH, N(C 1 -C 4 alkyl) 2 , d-d alkoxy,
• R 1 is independently H or F
• R 3A is independently selected from: F, CH 3 , -CH 2 OH, CH 2 F, CHF 2 , CF 3 , and
• the present disclosure includes a compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, within the scope of the first or second aspect; wherein:
• R 1 is independently H or F
• R 2 is H
• R 3 is independently a 5-membered heteroaryl comprising carbon atoms and 1 -4 heteroatoms selected from N, NR a , O, and S(0) p ; wherein said heteroaryl is substituted with 0-3 R 3A ; and
• the present disclosure includes a compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, within the scope of any one of the first, second and tenth aspects; wherein:
• R 3 is independently selected from: [0026]
• the present disclosure includes a compound of Formula (I) or (IA), or a pharmaceutically acceptable salt thereof, within the scope of any one of the first, second and tenth aspects; wherein:
• R is independently selected from: , , and
• the present disclosure includes a compound of Formula (I) (IA), or (IA-1), or a pharmaceutically acceptable salt thereof, within the scope of any of the above aspects, wherein:
• R 1 is F.
• the present disclosure provides a compound selected from the exemplified examples or a pharmaceutically acceptable salt thereof, including all compounds of Examples 1 to 245.
• the present disclosure provides a compound selected
• Example 1 In another embodiment, provided is a compound of Example 1 or a pharmaceutically acceptable salt thereof, wherein the compound is 8-(1 ,3-dimethyl-1 H- pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-[1 ,2,4]triazolo[4,3- c]pyrimidin-5-amine.
• Example 1 In another embodiment, provided is a compound of Example 1 , wherein the compound is 8-(1 ,3-dimethyl-1 H-pyrazol-5-yl)-N-((5-fluoro-2,3-dihydrobenzofuran-4- yl)methyl)-[1 ,2,4]triazolo[4,3-c]pyrimidin-5-amine.
• Example 2 In another embodiment, provided is a compound of Example 2 or a pharmaceutically acceptable salt thereof, wherein the compound is /V-((5-fluoro-2,3- dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1 ,2,4]triazolo[4,3-c]pyrimidin-5- amine.
• Example 2 In another embodiment, provided is a compound of Example 2, wherein the compound is /V-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)- [1 ,2,4]triazolo[4,3-c]pyrimidin-5-amine.
• Example 5 In another embodiment, provided is a compound of Example 5 or a pharmaceutically acceptable salt thereof, wherein the compound is /V-((5-fluoro-2,3- dihydrobenzofuran-4-yl)methyl)-8-(6-methoxy-4-methylpyridin-3-yl)-[1 ,2,4]triazolo[4,3- c]pyrimidin-5-amine.
• Example 5 In another embodiment, provided is a compound of Example 5, wherein the compound is /V-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(6-methoxy-4- methylpyrid in-3-yl)-[1 ,2,4]triazolo[4,3-c]pyrimidin-5-amine.
• Example 8 In another embodiment, provided is a compound of Example 8 or a pharmaceutically acceptable salt thereof, wherein the compound is 8-(2-cyclopropyl-4- methylpyrimidin-5-yl)-/V-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-[1 ,2,4]triazolo[4,3- c]pyrimidin-5-amine.
• a compound of Example 8 wherein the compound is 8-(2-cyclopropyl-4-methylpyrimidin-5-yl)-/V-((5-fluoro-2,3- dihydrobenzofuran-4-yl)methyl)-[1 ,2,4]triazolo[4,3-c]pyrimidin-5-amine.
• a compound of Example 207 or a pharmaceutically acceptable salt thereof wherein the compound is N-((5- fluorobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1 ,2,4]triazolo[4,3-c]pyrimidin-5- amine.
• Example 207 provides a compound of Example 207, wherein the compound is N-((5-fluorobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)- [1 ,2,4]triazolo[4,3-c]pyrimidin-5-amine.
• Example 233 In another embodiment, provided is a compound of Example 233 or a pharmaceutically acceptable salt thereof, wherein the compound is /V-((5-fluoro-2,3- dihydrobenzofuran-4-yl)methyl)-8-(4-methyl-1 H-imidazol-1 -yl)-[1 ,2,4]triazolo[4,3- c]pyrimidin-5-amine.
• Example 233 In another embodiment, provided is a compound of Example 233, wherein the compound is /V-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(4-methyl-1 H-imidazol-1 - yl)-[1 ,2,4]triazolo[4,3-c]pyrimidin-5-amine.
• the present disclosure provides a compound or a pharmaceutically acceptable salt thereof, selected from any subset list of compounds within the scope of the thirteenth aspect.
• a compound or a pharmaceutically acceptable salt thereof selected from any subset list of compounds within the scope of the thirteenth aspect.
• provided is the compound or a pharmaceutically acceptable salt thereof, within the scope of any one of the first to seventh aspects, wherein:
• R 3 is independently ;
• each R is independently selected from: C 1 -C 4 alkyl, C 1 -C 4 alkoxy,
• R 3 is independently ;
• R 3 is independently
• each R 3A is independently selected from: C 1 -C 4 alkoxy, C C 4 haloalkoxy, and -0-C 3 -C 6 cycloalkyl.
• R 3 is independently
• each R 3A is independently selected from: OCH 3 , OCH 2 CH 3 , -OCHF 2 , and -O-cyclopropyl.
• each R 3A is independently selected from: C 1 -C 4 alkoxy, C C 4 haloalkoxy, and -0-C 3 -C 6 cycloalkyl.
• R 3 is independently ;
• each R 3A is independently selected from: halogen, CN, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C C 4 haloalkyl, C C 4 haloalkoxy, N(C 1 -C 4 alkyl) 2 , and C 3 -C 6 cycloalkyl.
• halogen CN, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C C 4 haloalkyl, C C 4 haloalkoxy, N(C 1 -C 4 alkyl) 2 , and C 3 -C 6 cycloalkyl.
• R 3 is independently ;
• each R 3A is independently selected from: halogen, CN,
• R 3B is independently selected from: OH, NH 2 , N(C 1 -C 4 alkyl) 2 , and
• R 3c is independently selected from: C C 4 alkyl and 1 H-piperidin-4-yl.
• the present disclosure includes a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, within the scope of any one of the first, second, tenth, and eleventh aspects; wherein:
• R J is independently selected from:
• the present disclosure includes a compound of Formula (IA), or a pharmaceutically acceptable salt thereof, within the scope of any one of the first, second, tenth, and eleventh aspects; wherein:
• R 3 is independently
• each R 3A is independently selected from: C C 4 alkyl, C 1 -C 4 alkoxy,
• R a is independently selected from: H, C C 4 alkyl substituted with 0-1 R b , and C 3 -C 6 cycloalkyl;
• R b is independently selected from: OH and CrC 4 alkoxy.
• the compounds of the present disclosure have IC50 values ⁇ 5 ⁇ , using the EED Alphascreen binding, LC-MS and/or ELISA assays disclosed herein, preferably, IC50 values ⁇ 1 ⁇ , more preferably, IC50 values ⁇ 0.5 ⁇ , even more preferably, IC50 values ⁇ 0.1 ⁇ . II. OTHER EMBODIMENTS
• the present disclosure provides a composition comprising at least one of the compounds of the present disclosure or a
• the present disclosure provides a pharmaceutical composition
• a pharmaceutical composition comprising at least one of the compounds of the present disclosure or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, diluent or excipient.
• the present disclosure provides a pharmaceutical composition, comprising a therapeutically effective amount of at least one of the compounds of the present disclosure or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, diluent or excipient.
• the pharmaceutical composition is useful in the treatment of diseases or disorders mediated by EED and/or PRC2.
• the present disclosure provides a pharmaceutical composition as defined above further comprising additional therapeutic agent(s).
• the present disclosure provides a process for making a compound of the present disclosure.
• the present disclosure provides an intermediate for making a compound of the present disclosure.
• the present disclosure provides a compound of the present disclosure, for use in therapy, alone, or optionally in combination with another compound of the present disclosure and/or at least one other type of therapeutic agent.
• the present disclosure provides a compound of the present disclosure for use in therapy, for the treatment of diseases or disorders mediated by EED and/or PRC2, alone, or optionally in combination with another compound of the present disclosure and/or at least one other type of therapeutic agent.
• the present disclosure provides a method for the treatment of diseases or disorders mediated by EED and/or PRC2, comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one of the compounds of the present disclosure, alone, or optionally in combination with another compound of the present disclosure and/or at least one other type of therapeutic agent.
• the present disclosure provides a method for the treatment of diseases or disorders mediated by EED and/or PRC2, comprising administering to a patient in need thereof a therapeutically effective amount of a first and second therapeutic agent, wherein the first therapeutic agent is a compound of the present disclosure and the second therapeutic agent is one other type of therapeutic agent.
• the present disclosure also provides the use of a compound of the present disclosure for the manufacture of a medicament for the treatment of diseases or disorders mediated by EED and/or PRC2, alone, or optionally in combination with another compound of the present disclosure and/or at least one other type of therapeutic agent.
• the present disclosure provides a combined preparation of a compound of the present disclosure and additional therapeutic agent(s) for use in therapy.
• the present disclosure provides a combination of a compound of the present disclosure and additional therapeutic agent(s) for simultaneous or separate use in therapy.
• the present disclosure provides a combined preparation of a compound of the present disclosure and additional therapeutic agent(s) for simultaneous, separate or sequential use in the treatment of diseases or disorders mediated by EED and/or PRC2.
• the compound may be administered as a
• Examples of diseases or disorders mediated by EED and/or PRC2 include, but are not limited to, diffused large B cell lymphoma (DLBCL), follicular lymphoma, other lymphomas, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, brain tumors including neurobalstoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharhyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, and soft tissue sarcomas selected from rhabdomyosarcoma (RM
• the present disclosure provides a method for the treatment of diseases or disorders mediated by EED and/or PRC2, comprising administering to a patient in need thereof a therapeutically effective amount of a first optionally with a second therapeutic agent, wherein the first therapeutic agent is an EED inhibitor and the second therapeutic agent is one other type of therapeutic agent;
• diseases or disorders are selected from diffused large B cell lymphoma (DLBCL), follicular lymphoma, other lymphomas, leukemia, multiple myeloma, gastric cancer, malignant rhabdoid tumor, and hepatocellular carcinoma.
• DLBCL diffused large B cell lymphoma
• follicular lymphoma other lymphomas
• leukemia multiple myeloma
• gastric cancer malignant rhabdoid tumor
• hepatocellular carcinoma hepatocellular carcinoma
• additional therapeutic agent(s) used in combined pharmaceutical compositions or combined methods or combined uses are selected from one or more, preferably one to three, of the following therapeutic agents: other anticancer agents, immunomodulators, anti-allergic agents, anti-nausea agents (or antiemetics), pain relievers, cyto protective agents, and combinations thereof.
• heteroatoms refers to nitrogen (N), oxygen (O) or sulfur (S) atoms, in particular nitrogen or oxygen.
• N nitrogen
• O oxygen
• S sulfur
• any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.
• alkyl refers to a hydrocarbon radical of the general formula C n H 2n +i .
• the alkane radical may be straight or branched.
• Ci-C 10 alkyl or C ⁇ to C 10 alkyl refers to a monovalent, straight, or branched aliphatic group containing 1 to 10 carbon atoms (e.g., methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, 1 -methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, 3,3-dimethylpropyl, hexyl, 2-methylpentyl, heptyl, and the like).
• alkylene refers to a divalent alkyl group.
• C -C 6 alkylene or “C ⁇ to C 6 alkylene” refers to a divalent, straight, or branched aliphatic group containing 1 to 6 carbon atoms (e.g., methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), n-propylene (-CH 2 CH 2 CH 2 -), iso-propylene (-CH(CH 3 )CH 2 -), n-butylene, sec-butylene, iso-butylene, tert-butylene, n-pentylene, isopentylene, neopentylene, n-hexylene and the like).
• alkoxy refers to an alkyl linked to an oxygen, which may also be represented as -O-R or -OR, wherein the R represents the alkyl group.
• C -C 6 alkoxy or “C ⁇ to C 6 alkoxy” is intended to include C 2 , C 3 , C 4 , C 5 , and C 6 alkoxy groups.
• Example alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g. , n-propoxy and isopropoxy), and f-butoxy.
• alkylthio or “thioalkoxy” represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example methyl-S- and ethyl-S-.
• Halogen or "halo” may be fluorine, chlorine, bromine or iodine (preferred halogens as substituents are fluorine and chlorine).
• Haloalkyi is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with one or more halogens.
• haloalkyi include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl.
• haloalkyi also include "fluoroalkyl” that is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with one or more fluorine atoms.
• Haloalkoxy represents a haloalkyi group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
• C -C 6 haloalkoxy or “ ⁇ to C 6 haloalkoxy” is intended to include Ci , C 2 , C 3 , C 4 , C 5 , and C 6 haloalkoxy groups.
• Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluorothoxy.
• haloalkylthio or “thiohaloalkoxy” represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example
• oxo or -C(O)- refers to a carbonyl group.
• a ketone, aldehyde, or part of an acid, ester, amide, lactone, or lactam group for example, a ketone, aldehyde, or part of an acid, ester, amide, lactone, or lactam group.
• cycloalkyl refers to nonaromatic carbocyclic ring that is fully hydrogenated ring, including mono-, bi- or poly-cyclic ring systems.
• C 3 -C 8 cycloalkyl or " C 3 to C 8 cycloalkyl " is intended to include C 3 , C 4 , C 5 , C 6 , C 7 and C 8 cycloalkyl groups.
• Example cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornyl.
• aryl refers to 6- to 10-membered aromatic carbocyclic moieties having a single (e.g., phenyl) or a fused ring system (e.g., naphthalene.).
• a typical aryl group is phenyl group.
• benzyl refers to a methyl group on which one of the hydrogen atoms is replaced by a phenyl group.
• R is hydrogen, C ⁇ alkyl or a nitrogen protecting group (for example, carbobenzyloxy, p-methoxybenzyl carbonyl, t-butoxycarbonyl, acetyl, benzoyl, benz
• a 3 to 8 membered heterocycloalkyl includes epoxy, aziridinyl, azetidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydrothienyl 1 ,1 -dioxide, oxazolidinyl, thiazolidinyl, pyrrolidinyl, pyrrolidinyl-2-one, morpholino, piperazinyl, piperidinyl, piperidinylone, pyrazolidinyl, hexahydropyrimidinyl, 1 ,4-dioxa-8-aza-spiro[4.5]dec-8-yl, thiomorpholino,
• Partially saturated heterocyclic rings include groups such as
• a partially saturated heterocyclic ring also includes groups wherein the heterocyclic ring is fused to an aryl or heteroaryl ring (e.g., 2,3-dihydrobenzofuranyl, indolinyl (or 2,3-dihydroindolyl), 2,3- dihydrobenzothiophenyl, 2,3-dihydrobenzothiazolyl, 1 ,2,3,4-tetrahydroquinolinyl, 1 ,2,3,4- tetrahydroisoquinolinyl, 5,6,7,8-tetrahydropyrido[3,4-b]pyrazinyl, and the like).
• aryl or heteroaryl ring e.g., 2,3-dihydrobenzofuranyl, indolinyl (or 2,3-dihydroindolyl), 2,3- dihydrobenzothiophenyl, 2,3-dihydrobenzothiazolyl, 1 ,2,3,4
• partially or fully saturated heterocycle refers to a nonaromatic ring that is either partially or fully hydrogenated and may exist as a single ring, bicyclic ring (including fused rings) or a spiral ring.
• the heterocyclic ring is generally a 3- to 12-membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen and/or nitrogen.
• heterocycloalkyl and “partially saturated heterocycle”.
• spiral rings include 2,6-diazaspiro[3.3]heptanyl, 3-azaspiro[5.5]undecanyl, 3,9-diazaspiro[5.5]undecanyl, and the like.
• heteroaryl refers to aromatic moieties containing at least one heteroatom (e.g., oxygen, sulfur, nitrogen or combinations thereof) within a 5- to 10- membered aromatic ring system (e.g., pyrrolyl, pyridyl, pyrazolyl, indolyl, indazolyl, thienyl, furanyl, benzofuranyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, tetrazolyl, triazinyl, pyrimidinyl, pyrazinyl, thiazolyl, purinyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzopyranyl, benzothiophenyl, benzoimidazolyl, benzoxazolyl, 1 H- benzo[d][1 ,2,3]triazolyl, and the like.).
• the heteroaromatic moiety may consist of a single or fused ring system.
• a typical single heteroaryl ring is a 5- to 6-membered ring containing one to four heteroatoms independently selected from oxygen, sulfur and nitrogen and a typical fused heteroaryl ring system is a 9- to 10-membered ring system containing one to four heteroatoms independently selected from oxygen, sulfur and nitrogen.
• the fused heteroaryl ring system may consist of two heteroaryl rings fused together or a heteroaryl fused to an aryl (e.g., phenyl).
• heterocycloalkyl partially or fully saturated heterocycle
• partially saturated heterocycle partially saturated heterocycle
• heteroaryl partially saturated heterocycle
• a dotted ring When a dotted ring is used within a ring structure, this indicates that the ring structure may be saturated, partially saturated or unsaturated.
• substituted means that at least one hydrogen atom is replaced with a non-hydrogen group, provided that normal valencies are maintained and that the substitution results in a stable compound.
• 2 hydrogens on the atom are replaced.
• Keto substituents are not present on aromatic moieties.
• nitrogen atoms e.g. , amines
• these may be converted to N-oxides by treatment with an oxidizing agent (e.g. , mCPBA and/or hydrogen peroxides) to afford other compounds of this disclosure.
• an oxidizing agent e.g. , mCPBA and/or hydrogen peroxides
• shown and claimed nitrogen atoms are considered to cover both the shown nitrogen and its N-oxide (N ⁇ 0) derivative.
• any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence.
• a group is shown to be substituted with 0-3 R groups, then said group may be unsubstituted or substituted with up to three R groups, and at each occurrence R is selected independently from the definition of R.
• R 3A in the R 3 definition such that when R 3 is phenyl or 5- to 6-membered heteroaryl, these groups are either unsubstituted (not substituted with R 3A ) or substituted with one, two or three R 3A groups which are independently selected at each occurrence from the given definitions for R 3A .
• R 3 is phenyl or 5- to 6-membered heteroaryl
• R 3A is phenyl or 5- to 6-membered heteroaryl
• this disclosure is intended to cover all possible tautomers even when a structure depicts only one of them.
• phrases "pharmaceutically acceptable” indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
• the term "compounds of the present invention” or “compounds of the present disclosure” refers to compounds of Formula (I), (IA) or (IA-1), as well as isomers, such as stereoisomers (including diastereoisomers, enantiomers and racemates), geometrical isomers, conformational isomers (including rotamers and astropisomers), tautomers, isotopically labeled compounds (including deuterium substitutions), and inherently formed moieties (e.g., polymorphs, solvates and/or hydrates). When a moiety is present that is capable of forming a salt, then salts are included as well, in particular pharmaceutically acceptable salts.
• Enantiomers are a pair of stereoisomers that are non- superimposable mirror images of each other.
• a 1 :1 mixture of a pair of enantiomers is a "racemic” mixture. The term is used to designate a racemic mixture where appropriate.
• a single stereoisomer with known relative and absolute configuration of the two chiral centers is designated using the conventional RS system (e.g., (1 S.2S)); a single stereoisomer with known relative configuration but unknown absolute configuration is designated with stars (e.g., (1 R*,2R*)); and a racemate with two letters (e.g, (1 RS.2RS) as a racemic mixture of (1 R.2R) and (1 S.2S); (1 RS.2SR) as a racemic mixture of (1 R.2S) and (1 S.2R)).
• the conventional RS system e.g., (1 S.2S
• stars e.g., (1 R*,2R*
• a racemate with two letters e.g, (1 RS.2RS) as a racemic mixture of (1 R.2R) and (1 S.2S
• (1 RS.2SR a racemic mixture of (1 R.2S) and (1 S.2R
• Diastereoisomers are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
• the absolute stereochemistry is specified according to the Cahn- Ingold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
• Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Alternatively, the resolved compounds can be defined by the respective retention times for the corresponding
• Geometric isomers may occur when a compound contains a double bond or some other feature that gives the molecule a certain amount of structural rigidity. If the compound contains a double bond , the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration .
• Conformational isomers are isomers that can differ by rotations about one or more a bonds. Rotamers are conformers that differ by rotation about only a single a bond.
• atropisomer refers to a structural isomer based on axial or planar chirality resulting from restricted rotation in the molecule.
• Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques (e.g. , separated on chiral SFC or HPLC chromatography columns, such as CHIRALPAK® and CHIRALCEL® available from DAICEL Corp. using the appropriate solvent or mixture of solvents to achieve good separation).
• the present compounds can be isolated in optically active or racemic forms.
• Optically active forms may be prepared by resolution of racemic forms or by synthesis from optically active starting materials. All processes used to prepare compounds of the present disclosure and intermediates made therein are considered to be part of the present disclosure. When enantiomeric or diastereomeric products are prepared, they may be separated by conventional methods, for example, by chromatography or fractional crystallization.
• the end products of the present disclosure are obtained either in free (neutral) or salt form. Both the free form and the salts of these end products are within the scope of the disclosure. If so desired, one form of a compound may be converted into another form. A free base or acid may be converted into a salt; a salt may be converted into the free compound or another salt; a mixture of isomeric compounds of the present disclosure may be separated into the individual isomers. [00112] Pharmaceutically acceptable salts are preferred. However, other salts may be useful, e.g. , in isolation or purification steps which may be employed during preparation, and thus, are contemplated within the scope of the disclosure.
• pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
• pharmaceutically acceptable salts include, but are not limited to, acetate, ascorbate, adipate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, caprate,
• chloride/hydrochloride chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate/hydroxymalonate, mandelate, mesylate, methylsulphate, mucate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phenylacetate, phosphate/hydrogen phosphate/dihydrogen phosphate,
• subsalicylate, tartrate, tosylate, trifluoroacetate or xinafoate salt form
• Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids.
• Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, preferably hydrochloric acid.
• Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
• Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
• Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
• the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
• Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
• organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
• the pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Allen, L.V., Jr., ed.,
• Compounds of the invention that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers.
• These co-crystals may be prepared from compounds of the present invention by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of the present invention with the co-crystal former under crystallization conditions and isolating co- crystals thereby formed.
• Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of the present invention.
• any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
• Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
• isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 CI, 125 l respectively.
• the present disclosure includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H, 13 C, and 14 C , are present.
• Such isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
• PET positron emission tomography
• SPECT single-photon emission computed tomography
• an 18 F or labeled compound may be particularly desirable for PET or SPECT studies.
• Isotopically labeled compounds of this present disclosure can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
• substitution with heavier isotopes may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index.
• deuterium in this context is regarded as a substituent of a compound of the present disclosure.
• concentration of such a heavier isotope, specifically deuterium may be defined by the isotopic enrichment factor.
• isotopic enrichment factor as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
• a substituent in a compound of this invention is denoted deuterium
• such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium
• Isotopically-labeled compounds of the present disclosure can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
• Such compounds have a variety of potential uses, e.g. , as standards and reagents in determining the ability of a potential pharmaceutical compound to bind to target proteins or receptors, or for imaging compounds of this disclosure bound to biological receptors in vivo or in vitro.
• “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. It is preferred that compounds of the present disclosure do not contain a N-halo, S(0)2H, or S(0)H group.
• solvate means a physical association of a compound of this disclosure with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
• the solvent molecules in the solvate may be present in a regular arrangement and/or a non-ordered arrangement.
• the solvate may comprise either a stoichiometric or nonstoichiometric amount of the solvent molecules.
• “Solvate” encompasses both solution-phase and isolable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.
• polymorph(s) refer to crystalline form(s) having the same chemical structure/composition but different spatial arrangements of the molecules and/or ions forming the crystals.
• Compounds of the present disclosure can be provided as amorphous solids or crystalline solids. Lyophilization can be employed to provide the compounds of the present disclosure as a solid.
• EED refers to the protein product of the gene embryonic ectoderm development.
• PRC2 refers to Polycomb Repressive Complex 2.
• PRC2-mediated disease or disorder refers to any disease or disorder which is directly or indirectly regulated by PRC2. This includes, but is not limited to, any disease or disorder which is directly or indirectly regulated by EED.
• diseases or disorders mediated by EED and/or PRC2 refers to diseases or disorders which are directly or indirectly regulated by EED and/or PRC2.
• patient encompasses all mammalian species.
• the term "subject” refers to an animal. Typically the animal is a mammal. A “subject” also refers to any human or non-human organism that could potentially benefit from treatment with an EED inhibitor. A subject also refers to for example, primates (e.g. , humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human. Exemplary subjects include human beings of any age with risk factors for cancer disease.
• a subject is "in need of a treatment if such subject would benefit biologically, medically or in quality of life from such treatment (preferably, a human).
• the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
• the term "treat', "treating” or “treatment” of any disease/ disorder refers to the treatment of the disease/disorder in a mammal, particularly in a human, and includes: (a) ameliorating the disease/disorder, (i.e. , slowing or arresting or reducing the development of the disease/disorder, or at least one of the clinical symptoms thereof); (b) relieving or modulating the disease/disorder, (i.e., causing regression of the disease/disorder, either physically, (e.g.
• stabilization of a discernible symptom physiologically, (e.g., stabilization of a physical parameter), or both); (c) alleviating or ameliorating at least one physical parameter including those which may not be discernible by the subject; and/or (d) preventing or delaying the onset or development or progression of the disease or disorder from occurring in a mammal, in particular, when such mammal is predisposed to the disease or disorder but has not yet been diagnosed as having it.
• preventing or “prevention” cover the preventive treatment (i.e., prophylaxis and/or risk reduction) of a subclinical disease-state in a mammal, particularly in a human, aimed at reducing the probability of the occurrence of a clinical disease-state.
• Patients are selected for preventative therapy based on factors that are known to increase risk of suffering a clinical disease state compared to the general population.
• "Prophylaxis” therapies can be divided into (a) primary prevention and (b) secondary prevention.
• Primary prevention is defined as treatment in a subject that has not yet presented with a clinical disease state, whereas secondary prevention is defined as preventing a second occurrence of the same or similar clinical disease state.
• risk reduction covers therapies that lower the incidence of development of a clinical disease state.
• primary and secondary prevention therapies are examples of risk reduction.
• “Therapeutically effective amount” is intended to include an amount of a compound of the present disclosure that will elicit the biological or medical response of a subject, for example, reduction or inhibition of EED and/or PRC2, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease or disorder mediated by PRC2.
• the term refers to combined amounts of the active ingredients that result in the preventive or therapeutic effect, whether administered in combination, serially, or simultaneously.
• the compounds of the present disclosure can be prepared in a number of ways known to one skilled in the art of organic synthesis in view of the methods, reaction schemes and examples provided herein.
• the compounds of the present disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.
• the reactions are performed in a solvent or solvent mixture appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the disclosure
• the starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wis.) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1 -19, Wiley, New York (1967-1999 ed.), Larock, R.C., Comprehensive Organic Transformations, 2 nd -ed., Wley-VCH Weinheim, Germany (1999), or Beilsteins Handbuch der organischen
• reaction schemes depicted below provide potential routes for synthesizing the compounds of the present disclosure as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section below. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the inventive compounds. Although specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.
• Scheme 1 describes potential routes for producing the compounds of the present disclosure which include compounds of Formula (IA).
• Compounds of Formula (IA) can be made substantially optically pure by either using substantially optically pure starting material or by separation chromatography, recrystallization or other separation techniques well-known in the art. For a more detailed description, see the Example section below.
• Reverse phase preparative HPLC was carried out using C18 columns with UV 214 nm and 254 nm or prep LC-MS detection eluting with gradients of Solvent A (water with 0.1 % TFA) and Solvent B (acetonitrile with 0.1 % TFA) or with gradients of Solvent A (water with 0.05% TFA) and Solvent B (acetonitrile with 0.05% TFA) or with gradients of Solvent A (water with 0.05% ammonia) and Solvent B ( acetonitrile with 0.05% ammonia).
• Reverse phase analytical HPLC/MS was performed on Agilent LC1200 systems coupled with 61 10 (Methods A-D), or 6120 (Method E and F), or 6130 (Method G) Mass Spectrometer.
• Method A Linear gradient of 5% to 95% B over 1.2 min, with 1 min hold at 95% B; UV visualization at 214 nm and 254 nm
• Solvent A 0.1 % trifluoroacetic acid, 99.9% water
• Solvent B 0.1 % trifluoroacetic acid, 99.9% acetonitrile.
• Method B Linear gradient of 5% to 95% B over 1.5 min, with 1 min hold at 95% B;
• Solvent A water with 10mM Ammonium hydrogen carbonate
• Solvent B acetonitrile
• Solvent A 0.1 % trifluoroacetic acid, 99.9% water
• Solvent B 0.1 % trifluoroacetic acid, 99.9% acetonitrile.
• Method D Linear gradient of 5% to 95% B over 1.4 min, with 1.6 min hold at 95% B,
• Solvent A water with 10mM Ammonium hydrogen carbonate
• Solvent B acetonitrile
• Method E Linear gradient of 5% to 95% B over 1.5 min, with 1 min hold at 95% B;
• Solvent A water with 10mM Ammonium hydrogen carbonate
• Solvent B acetonitrile
• Method F Linear gradient of 5% to 95% B over 1 .5 min, with 1 min hold at 95% B;
• Solvent A water with 0.1 % ammonia
• Solvent B acetonitrile.
• Method G Linear gradient of 10% to 95% B over 2 min, with 1 min hold at 95% B;
• UV visualization at 214 nm, 254 nm and 300 nm
• Solvent B MeOH with 0.1 % formic acid.
• starting materials are generally available from a non-excluding commercial sources such as TCI Fine Chemicals (Japan), Shanghai Chemhere Co., Ltd. (Shanghai, China), Aurora Fine Chemicals LLC (San Diego, CA), FCH Group (Ukraine), Aldrich Chemicals Co. (Milwaukee, Wis.), Lancaster Synthesis, Inc. (Windham, N.H.), Acros Organics (Fairlawn, N.J.), Maybridge Chemical Company, Ltd. (Cornwall, England), Tyger Scientific (Princeton, N.J.), AstraZeneca
• Methyl 2-methylbenzofuran-7-carboxylate (A3.2): A mixture of A3.1 (1 .0 g, 5.26 mmol) and cesium fluoride (1 .038 g, 6.84 mmol) in N,N-diethylaniline (5 mL, 5.26 mmol) was irritated by microwave at 200 °C for 30 min. After diluted with ehter insoluble materails were removed by decantation. The crude products were seperated on column chromatography by using a mixed solvent of hexane and ethyl acetate(10:1 , v/v) to give the title compound (500 mg, 50%).
• tert-Butyl 4-(5-bromopyridin-2-yl)-3-oxopiperazine-1-carboxylate (B16.1): A mixture of 2,5-dibromopyridine (1 .0 g, 4.21 mmol), pyrrolidin-2-one (2.54 g, 12.7 mmol), K 2 C0 3 (1 .16 g, 8.42 mmol) , Cul (40 mg , 0.21 mmol), N1 ,N1 ,N2,N2-tetramethylethane- 1 ,2-diamine (92 mg , 0.63 mmol) and dioxane (10 mL) was stirred at 1 10 °C for 12 h.
• B24.1 4-(5-bromo-3-methylpyridin-2-yl)morpholine (B24.1): A mixture of 5-bromo-2- fluoro-3-methylpyridine (2.5 g, 13.2 mmol), morpholine (3.4 g, 39.6 mmol), K 2 C0 3 (5.5 g, 39.6 mmol) in 40 mL DMSO was heated to 120 °C and stirred for 16 h. The mixture was cooled to rt. 200 mL water was added, extracted with ethyl acetate (150 mL ⁇ 3).
• Methyl(m-tolyl)sulfane (B29.1): To a mixture of 3-methylbenzenethiol (2 g, 16 mmol) in 20 mL of DMF was added NaH (0.96 g, 24 mmol) at 0 °C. The mixture was stirred for 30 min at 25 °C. After coolig to 0 °C, CH 3 I (22.7 g, 160 mmol) was added dropwise. The mixture was stirred for 2 h at rt, diluted with 100 mL water, extracted with ethyl acetate (60 mL ⁇ 3).
• (E)-Ethyl 3-(5-bromopyridin-2-yl)acrylate (B30.1): A mixture of 5- bromopicolinaldehyde (0.93 g, 5 mmol), ethyl 2-bromoacetate (1 .25 g, 7.5 mmol), NaHC0 3 (1 .26 g, 15 mmol), PPh 3 (1 .83 g, 7 mmol) , water (10 mL) in 5 mL ethyl acetate was stirred for 16 h at 25 °C under N 2 atmosphere.
• LC-MS: [M+H] + 260.0.
• Example 2 was prepared as follows. To a suspension of A1 (25.5 g, 70 mmol), 2-methyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine (30.6 g, 140 mmol) and NaHC0 3 (35.3 g, 420 mmol) in a mixture solution of 1 ,4-dioxane (300 ml_) and H 2 0 (100 ml_) was added PdCI 2 (dppf) (5.94 g, 612 mmol). The mixture was degassed with N 2, heated at 1 10 °C for 1 h. The resulting mixture was cooled to rt and conentrated under reduced pressure.
• A1 25.5 g, 70 mmol
• 2-methyl-3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine 30.6 g, 140 mmol
• NaHC0 3 35.3 g, 420 m
• Example 2 (13.6 g, 52%) 1 H-NMR (500 MHz, DMSO-c/ 6 ) ⁇ ppm 2.40 (s, 3H), 3.33 (t, 2H), 4.56 (t, 2H), 4.72 (s, 2H), 6.72 (dd, 1 H), 6.96 (dd, 1 H), 7.31 (dd, 1 H), 7.66 (s, 1 H), 7.74 (d, 1 H), 8.51 (d, 1 H), 8.72 (t, 1 H), 9.49 (s, 1 H).
• LC-MS: [M+H] + 376.9.
• Example 2 To a suspension of Example 2 (6.0 g, 15.94 mmol) in 100 mL of IPA, a solution of 0.5 N HCI in IPA (33.0 mL, 16.50 mmol) was added dropwise at rt. The suspension was stirred at 50 °C for 12 h, then cooled to rt and stirred for 5 h.
• Example 7 To a mixture 7.1 (30 mg, 0.08 mmol) in THF (3ml_) was added TBAF (0.6 mL, 0.6 mmol) and stirred for 4 h. The mixture was concentrated and purified by Prep-HPLC to afford the title compound (20 mg, 87%) as a white solid.
• N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(pyridin-3-yl)- [1,2,4]triazolo[4,3-c]pyrimidin-5-amine (10.1): The title compound was prepared by using a procedure similar to that of Example 1 by replacing 1 ,3-dimethyl-1 H-pyrazol-5- ylboronic acid with 3-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine.
• Example 10 To a mixture of 10.1 (1 10mg, 0.3mmol ) in CHCI 3 (5ml_) was added mCPBA (163mg, 0.6mmol).
• reaction mixture was purged with N 2 for 3 times, then stirred at 90 °C for 1 h.
• the mixture was filtered, the solid was washed with DMSO (2 mL).
• the filtrate was concentrated and purified by prep-HPLC (NH 4 HC0 3 ) to give the title comppound (13 mg, 48%) as a white solid.
• EED As a key component of PRC2 complex, EED has no intrinsic enzymatic activity. However, it is critical for proper PRC2 function. EED directly binds to H3K27me3 and this binding event localizes the PRC2 complex to the chromatin substrate and allosterically activates the methyltransferase activity. Targeting the allosteric site within the regulatory EED subunit of PRC2, may offer a novel and unique angle to be advantageous to, or complementary to, directly targeting the SAM competition mechanism of EZH2 or PRC2. Therefore, targeting EED represents a highly attractive strategy for the development of a novel therapy for the treatment of many forms of cancers. In particular, the need exists for small molecules that inhibit the activity of PRC2 through targeting EED. It has now been found that triazolopyrimidine derivatives as presently disclosed are useful to target EED for the treatment of EED or PRC2- mediated diseases or disorders, especially cancers.
• the utility of the compounds of the present invention may be demonstrated using any one of the following test procedures.
• Compounds of the present disclosure were assessed for their ability to inhibit PRC2 activity in a pentameric complex of EZH2, SUZ12, EED, Rbap48 and AEBP in biochemical assays.
• the ability of compounds of the present disclosure to inhibit cellular activity of PRC2 was assessed by analysing histone H3 lysine 27 methylation in human cell lines.
• the ability of compounds of the present disclosure to inhibit cancers was derived from their ability to modulate activity in human cancer cell lines bearing specific dependence to PRC2 activity to maintain cancerous growth.
• AlphaScreen detection beads mix was prepared immediately before use by mixing nickel chelate acceptor beads and streptavidin donor beads in a 1 :1 ratio (Perkin Elmer, Product No.6760619C/M/R) into the buffer described above. Then 4 ⁇ _ of detection beads mix was added to the plate and incubate in the dark at the rt for 1 h. The final concentration of donor and acceptor beads was 10 ⁇ g/mL for each. Plates were read on EnVision (PerkinElmer) using the AlphaScreen setting adapted for optimal signal detection with a 615 nm filter, after sample excitation at 680 nm. The emission signal at 615 nm was used to quantify compounds inhibition.
• AlphaScreen signals were normalized based on the reading coming from the positive (maximum signal control) and negative controls (minimum signal control) to give percentage of activities left. The data were then fit to a dose response equation using the program Helios (Novartis) to get the IC50 values.
• Helios is a Novartis in-house assay data analysis software using the methods described by Normolle, D. P., Statistics in Medicine, 12:2025-2042 (1993); Formenko, I. et al, Computer Methods and Programs in Biomedicine, 82, 31 -37 (2006); Sebaugh, J. L, Pharmaceutical Statistics, 10:128-134 (201 1); Kelly, C.
• AlphaScreen beads Compounds were diluted as described in the preceding section, and the assay was performed by adding 12 ⁇ of 10 nM biotin-miniPEG-His6 peptide in the above buffer and incubating for 20 min at rt prior to addition of the beads to10 ⁇ g/mL each. The plates were then incubated for 1 h at rt in dark before being read on EnVison. EED LC-MS Assay
• Representative compounds of the present disclosure were serially and separately diluted 3-fold in DMSO to obtain a total of eight or twelve concentrations. Then the test compounds at each concentration (120 nl_ of each) were transferred by Mosquito into a 384-well Perkin Elmer ProxiPlate 384 plus plates. Solutions (6 ⁇ _) of 24 nM the wild type PRC2 (wtPRC2) complex and 2 ⁇ SAM in reaction buffer (20 mM Tris, pH 8.0, 0.1 % BSA, 0.01 % Triton, 0.5 mM DTT) were added to the wells that were then incubated with the test compound for 20 min. A 6 ⁇ _ solution of 3 ⁇ of the peptide substrate
• H3K27MeO histone H3[21 -44]-biotin
• reaction buffer was added to initiate each reaction.
• the final components in the reaction solution include 12 nM wtPRC2 complex, 1 ⁇ SAM, and 1 .5 ⁇ H3K27meO peptide with varying concentration of the compounds.
• a positive control consisted of the enzyme, 1 ⁇ SAM and 1 .5 ⁇ substrate in the absence of the test compound, and a negative control consisted of 1 ⁇ SAM and 1 .5 ⁇ substrate only.
• Each reaction was incubated at rt for 120 min, then stopped by addition of 3 ⁇ _ per of quench solution (2.5% TFA with 320 nM d4-SAH).
• the reaction mixture was centrifuged (Eppendorf centrifuge 5810, Rotor A-4-62) for 2 min at 2000 rpm and read on an API 4000 triple quadrupole mass spec with Turbulon Spray (Applied Biosystem) coupled with Prominence UFLC (Shimadzu).
• the levels of SAH production were then normalized based on the values coming from the positive and negative controls to give percent enzyme activities.
• the data were then fit to a dose response equation using the program Helios to get the IC 50 values of the test compound.
• Representative compounds of the present disclosure were serially and separately diluted 3-fold in DMSO to obtain a total of eight or twelve concentrations.
• the plate was gently agitated at 4°C for 30 min.
• the cell lysate was neutralized with neutralization buffer (0.5 M sodium phosphate dibasic, pH 12.5, 1 mM DTT; 36 ⁇ _ per well).
• neutralization buffer 0.5 M sodium phosphate dibasic, pH 12.5, 1 mM DTT; 36 ⁇ _ per well. The plate was agitated to ensure the lysates were well mixed prior to the ELISA protocol.
• ELISA protocol Cell lysates were transferred to the wells of a 384-well plate and the final volume was adjusted to 50 ⁇ _ per well with PBS. The plate was sealed, centrifuged at 2,000 rpm for 2 min and incubated at 4°C for about 16 h. The plate was washed with TBST buffer (1 x TBS (1 Ox TBS: 24.2 g Tris (Sigma, T6066), 80 g NaCI (Sigma, S3014) to 1 L of water and adjust pH to 7.6 with HCI) with 0.1 % Tween-20). Blocking buffer (TBST, 5% BSA; 50 ⁇ _ per well) was added and the plate was incubated for 1 h at rt.
• the blocking buffer was removed and primary antibody was added (30 ⁇ _ per well).
• the following dilutions were performed with blocking buffer: for anti- H3K27me3 antibody (Cell Signaling Technology, #9733), dilution was 1 :1000; for anti- H3K27me2 antibody (Cell Signaling Technology, #9288), dilution was 1 :100; for anti-H3 antibody (Abeam, Cat#24834), dilution was 1 :1000.
• the primary antibody was incubated in the plate at rt for 1 h.
• the wells were washed with TBST and incubated with secondary antibody for 1 h at rt.
• Representative compounds of the present disclosure were analyzed for their ability to selectively inhibit PRC2.
• Western blot was performed using standard molecular biology techniques. Cell was lysed in SDS lysis buffer (Millipore, Cat#20-163) and protein concentration was measured by BCA protein assay (Pierce, Cat# PI-23221).
• Antibodies for western blots were purchased from Cell Signaling Technology (Danvers, MA, USA).
• Anti-H3K9me1 (#07- 395), anti-H3K27me1 (#07-448), and anti-H3K36me1 (#07-548) were purchased from Millipore (Billerica, MA, USA). Anti-H3K36me3 (ab9050-100) was purchased from Abeam (Cambridge, UK). Anti-H3K9me3 (#39161) was purchased from Active Motif (Carlsbad, CA, USA).
• Compounds of the present disclosure specifically inhibit the methylation of the PRC2 substrate H3K27. This can be demonstrated by their ability to inhibit H3K27me2 and H3K27me3 in a number of human cancer cell lines, examples include rhabdoid cells (G401) and lymphoma cells (WSU-DLCL2, KARPAS422, SU-DHL4). Selectivity is profiled against a number of other methylation marks, for example: H3K4me2;
• H3K9me2 H3K36me3; and H3K79me3.
• B cell lymphoma cell KARPAS422 was cultured using standard cell culture conditions in RPMI-1640 (Invitrogen, cat #1 1875) supplemented with 15% FBS
• a representative compound of the present disclosure was dissolved in 10% PEG300, 10% Solutol HS 15 and 80% pH 4.65 Acetate buffer to yield a final concentration of 0.2 mg/mL for intravenous (IV) and oral administration (PO).
• rat PK studies a total of three male Sprague Dawley rats each were used for rat IV and PO PK study, respectively.
• the formulation solution was administered via a single bolus IV at 1 mg/kg and a single oral gavage (PO) at 2 mg/kg, respectively.
• Blood samples (approximately 150 ⁇ _) were collected via jugular cannula at appropriate time points.
• PK parameters including area under concentration curve (AUC), mean residence time (MRT), plasma clearance (CI), steady state volume of distribution (Vdss), elimination half-life (t 1/2 ), maximum concentration (Cmax), time of maximum concentration (Tmax) and oral bioavailability (F %) were calculated using the following equations:
• t time and C is plasma concentration at the time (t);
• Dose iv is the dose for intravenous administration; and Dose ora i is the dose for oral administration.
• Vdss CI * MRT
• the cells Karpas 422 human B cell lymphoma were cultured in RPMI-1640 medium (Gibco; 1 1875-093) supplemented with 15% FBS (Gibco; 10099-141 ) and 1 % Pen Strep (Gibco; 15140-122) at 37°C in an atmosphere of 5% C02 in air. Cells were maintained in suspension cultures at concentrations between 0.5 - 2 x 10 6 cells/ml. Cells were split at 1 :3 every 2-4 days.
• the cells were collected, suspended in PBS, mixed with Matrigel (BD Bioscience) at a volume ratio of 1 :1 at a concentration of 1 x10 8 cells/mL and then injected subcutaneously into the right flank of balb/c nude mice (Vital River) at a concentration of 5x10 6 cells per animal.
• Matrigel BD Bioscience
• the compound was formulated as a suspension in 0.5% methyl cellulose (MC) and 0.5% Tween 80 in 50 mM pH6.8 buffer (prepared in house according to the USP) and administered orally by gavage at specific doses.
• MC methyl cellulose
• Tween 80 in 50 mM pH6.8 buffer (prepared in house according to the USP) and administered orally by gavage at specific doses.
• Treatment was initiated when the average tumor volume reached 100-300 mm 3 .
• Tumor growth and body weights were monitored at regular intervals.
• the two largest diameters, width (W) and length (L), of the xenograft tumors were measured manually with calipers and the tumor volume was estimated using the formula: 0.5 x L x W 2 .
• results are presented as mean ⁇ SEM. Graphing and statistical analysis was performed using GraphPad Prism 5.00 (GraphPad Software). Tumor and body weight change data were analyzed statistically. If the variances in the data were normally distributed (Bartlett's test for equal variances), the data were analyzed using one-way ANOVA with post hoc Dunnet's test for comparison of treatment versus control group. The post hoc Tukey test was used for intragroup comparison. Otherwise, the Kruskal-Wallis ranked test post hoc Dunn's was used.
• Tumor regression was calculated according to:
• Atumor volumes represent the mean tumor volume on the evaluation day minus the mean tumor volume at the start of the experiment.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Hematology (AREA)
• Oncology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (31)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (1)

Family

ID=55071101

Family Applications (1)

Country Status (40)

Cited By (24)

Families Citing this family (18)

Citations (15)

Family Cites Families (35)

• 2015
  • 2015-12-21 SG SG11201703880VA patent/SG11201703880VA/en unknown
  • 2015-12-21 MY MYPI2017701623A patent/MY186837A/en unknown
  • 2015-12-21 CN CN201580070691.5A patent/CN107108637B/zh active Active
  • 2015-12-21 AU AU2015370524A patent/AU2015370524B2/en active Active
  • 2015-12-21 CA CA2969090A patent/CA2969090C/en active Active
  • 2015-12-21 PE PE2017001154A patent/PE20171307A1/es unknown
  • 2015-12-21 HU HUE15820637A patent/HUE043060T2/hu unknown
  • 2015-12-21 NZ NZ731664A patent/NZ731664A/en unknown
  • 2015-12-21 LT LTEP15820637.5T patent/LT3237418T/lt unknown
  • 2015-12-21 SI SI201530725T patent/SI3237418T1/sl unknown
  • 2015-12-21 ME MEP-2019-127A patent/ME03385B/me unknown
  • 2015-12-21 KR KR1020177016880A patent/KR102534028B1/ko active IP Right Grant
  • 2015-12-21 BR BR112017010354A patent/BR112017010354B8/pt active IP Right Grant
  • 2015-12-21 RS RS20190502A patent/RS58679B1/sr unknown
  • 2015-12-21 DK DK15820637.5T patent/DK3237418T3/da active
  • 2015-12-21 WO PCT/IB2015/059843 patent/WO2016103155A1/en active Application Filing
  • 2015-12-21 US US15/538,348 patent/US10220036B2/en active Active
  • 2015-12-21 PL PL15820637T patent/PL3237418T3/pl unknown
  • 2015-12-21 UA UAA201704770A patent/UA120945C2/uk unknown
  • 2015-12-21 JP JP2017533767A patent/JP6736559B2/ja active Active
  • 2015-12-21 MX MX2017008529A patent/MX2017008529A/es active IP Right Grant
  • 2015-12-21 TN TN2017000204A patent/TN2017000204A1/en unknown
  • 2015-12-21 CR CR20170285A patent/CR20170285A/es unknown
  • 2015-12-21 PT PT15820637T patent/PT3237418T/pt unknown
  • 2015-12-21 EA EA201791420A patent/EA032416B1/ru not_active IP Right Cessation
  • 2015-12-21 UY UY0001036462A patent/UY36462A/es not_active Application Discontinuation
  • 2015-12-21 US US14/977,273 patent/US9580437B2/en active Active
  • 2015-12-21 EP EP15820637.5A patent/EP3237418B1/en active Active
  • 2015-12-21 ES ES15820637T patent/ES2722048T3/es active Active
  • 2015-12-22 JO JOP/2015/0331A patent/JO3489B1/ar active
  • 2015-12-22 TW TW104143216A patent/TWI694076B/zh active
• 2017
  • 2017-05-07 IL IL252135A patent/IL252135B/en active IP Right Grant
  • 2017-06-01 PH PH12017501016A patent/PH12017501016B1/en unknown
  • 2017-06-16 CL CL2017001572A patent/CL2017001572A1/es unknown
  • 2017-06-16 CO CONC2017/0005992A patent/CO2017005992A2/es unknown
  • 2017-06-21 DO DO2017000149A patent/DOP2017000149A/es unknown
  • 2017-06-23 GT GT201700146A patent/GT201700146A/es unknown
  • 2017-06-23 SV SV2017005472A patent/SV2017005472A/es unknown
  • 2017-07-20 EC ECIEPI201747153A patent/ECSP17047153A/es unknown
• 2019
  • 2019-01-11 US US16/246,380 patent/US20190142837A1/en not_active Abandoned
  • 2019-04-29 HR HRP20190805TT patent/HRP20190805T1/hr unknown
  • 2019-04-30 CY CY20191100456T patent/CY1121901T1/el unknown
• 2020
  • 2020-04-30 US US16/863,631 patent/US11207325B2/en active Active
• 2021
  • 2021-10-19 US US17/505,271 patent/US11931363B2/en active Active

Patent Citations (15)

Non-Patent Citations (28)

Also Published As

Similar Documents

Legal Events